Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Catheter Ablation “Reasonable” For Atrial Fibrillation When Drugs Fail - ACC

This article was originally published in The Gray Sheet

Executive Summary

New guidelines suggest catheter ablation moved up the evidence chain in recent years as a reasonable treatment for atrial fibrillation, but researchers say further study is still needed

You may also be interested in...



HRS A-Fib Ablation Consensus Statement Offers Clinical Trial Advice

A new expert 1consensus statement on ablation of atrial fibrillation, created by a Heart Rhythm Society task force, includes 21 specific recommendations for the design and conduct of clinical trials of AF ablation devices

HRS A-Fib Ablation Consensus Statement Offers Clinical Trial Advice

A new expert 1consensus statement on ablation of atrial fibrillation, created by a Heart Rhythm Society task force, includes 21 specific recommendations for the design and conduct of clinical trials of AF ablation devices

Research News In Brief

PREVENT-HF: CardioDynamics, manufacturer of the BioZ impedance cardiography system, launches the randomized, controlled PREVENT-HF trial to compare BioZ monitoring to standard clinical care for management of chronic heart failure. The trial is designed to demonstrate the value of impedance cardiography data in guiding treatment decisions and reduce hospitalizations of heart failure patients. The trial will enroll about 500 patients at 35 centers, and each patient will be followed from six to 12 months. The exact number of patients will be determined by the rate of adverse events; the trial will be complete when 212 heart failure-related hospitalizations have been recorded. PREVENT-HF is a follow-on trial to CardioDynamics' PREDICT study, which demonstrated that the proprietary BioZ scoring algorithm was a powerful and independent measure of risk for near-term, heart failure-related adverse events, including hospitalization, emergency room visits and death (1"The Gray Sheet" Sept. 20, 2004, p. 18)...

Related Content

UsernamePublicRestriction

Register

MT023835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel